Ispecimen Inc ( (ISPC) ) has released its Q2 earnings. Here is a breakdown of the information Ispecimen Inc presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
iSpecimen Inc. is a technology-driven company that operates an online marketplace platform connecting medical researchers with biospecimen suppliers, primarily in North America. In its latest earnings report for the quarter ending June 30, 2025, iSpecimen Inc. reported a significant decrease in revenue compared to the previous year, with total revenue of $713,135, down from $2,863,679. The company also reported a net loss of $1,047,243 for the quarter, an improvement from the $2,109,024 loss in the same period last year. Key financial metrics indicate a challenging period for iSpecimen, with a notable decline in cash and cash equivalents to $588,775 from $1,878,408 at the end of 2024. The company has been actively working to reduce costs, including a significant reduction in workforce and technology expenses, in an effort to improve its financial position. Looking forward, iSpecimen’s management remains focused on increasing revenues and managing expenditures to ensure the company’s sustainability, although uncertainties remain regarding the success of these efforts.